IN

IND Swift Laboratories LtdNSE INDSWFTLAB Stock Report

Last reporting period 31 Mar, 2024

Updated 18 Sep, 2024

Last price

Market cap $B

0.021

Micro

Exchange

XNSE - National Stock Exchange Of India

INDSWFTLAB.NS Stock Analysis

IN

Uncovered

IND Swift Laboratories Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

44/100

Low score

Market cap $B

0.021

Dividend yield

Shares outstanding

59.087 B

Ind-Swift Laboratories Ltd. engages in the manufacture, development, and market of pharmaceutical ingredients. The company is headquartered in Chandigarh, Chandigarh and currently employs 1,496 full-time employees. The company went IPO on 2002-03-15. The firm is engaged in the business of manufacturing intermediates and formulations. The Company’s products or services include Advanced Intermediates. The company is API partner for many organizations both in generic and innovative domains. The firm offers reference standards and impurities for various active pharmaceutical ingredients (APIs) under British Pharmacopoeia (BP), European Pharmacopoeia (EP), British Pharmacopoeia (BP) and others. Its impurity portfolio is stocked with a range of standards for supply. The firm offers reference standards and impurities for over 25 APIs. All impurities are shipped with full documentation, including a Certificate of Analysis and MSDS. The research center, spread over the area of 40,000 square feet, is engaged in developing process technology for APIs in different therapeutic categories.

View Section: Eyestock Rating